LC-MS/MS based bio analysis of desidustat: from development to application
DOI:
https://doi.org/10.69857/joapr.v14i2.2014Keywords:
Liquid Chromatography-Mass Spectrometry, Multiple Reaction Monitoring (Mrm), Bioanalytical Method, Pharmacokinetics, QuantificationAbstract
Background: Desidustat's potential as a medicinal treatment for anaemia has generated considerable interest. For pharmacokinetic analysis, therapeutic monitoring, and drug development research, precise quantification of Desidustat in biological matrices is crucial. Hence, more advanced methods are necessary for detection at minute concentrations (ng/mL level) in plasma. Methodology: A reverse-phase C18 column with an isocratic elution technique utilising acetonitrile and an aqueous buffer as mobile phase to accomplish chromatographic separation. To produce characteristic ion transitions for quantification, after electrospray ionization (ESI), tandem mass spectroscopy in positive ion mode was chosen for detection. The technique's linearity, sensitivity, precision, and accuracy were systematically improved and verified, and the validated method was successfully applied to pharmacokinetic studies. Results and Discussion: The developed method’s validation results confirmed good selectivity, sensitivity (LLOQ 6 ng/ml), excellent linearity, and acceptable precision and accuracy, with a remarkably low lower limit of quantification (LLOQ). Recovery and matrix effect studies showed minimal ion suppression and reproducible extraction efficiency. The stability of desidustat is demonstrated in rat plasma. Intra-day and inter-day precision and accuracy values were well within the acceptable limits prescribed by regulatory guidelines, confirming the method's reliability and reproducibility. The optimized LC–MS/MS conditions ensured high sensitivity and selectivity, making the method suitable for bioanalytical applications. Conclusion: A novel, highly sensitive, and reliable LC–MS/MS bioanalytical method for estimation of Desidustat in rat plasma was successfully developed and validated. The method provides a robust analytical tool to support pharmacokinetic studies, therapeutic monitoring, and future research related to Desidustat.
Downloads
References
Dhillon S. Desidustat: first approval. Drugs, 82, 1207–1212 (2022) https://doi.org/10.1007/s40265-022-01744-w
Parmar DV, Kansagra KA, Patel JC, Joshi SN, Sharma NS, Shelat AD, Patel NB, Nakrani VB, Shaikh FA, Patel HV. Outcomes of desidustat treatment in people with anemia and chronic kidney disease: a phase 2 study. Am. J. Nephrol., 49, 470–478 (2019) https://doi.org/10.1159/000500232
Akizawa T, Nobori K, Matsuda Y, Taki K, Hayashi Y, Hayasaki T, et al. Molidustat for the treatment of anaemia in Japanese patients undergoing peritoneal dialysis: a single-arm, open-label, phase 3 study. Ther. Apher. Dial., 26, 368–377 (2022) https://doi.org/10.1111/1744-9987.13713
Philip M, Karakka Kal AK, Subhahar MB, Karatt TK, Mathew B, Perwad Z. In vitro studies of hypoxia inducible factor–prolyl hydroxylase inhibitors daprodustat, desidustat, and vadadustat for equine doping control. Drug Test. Anal., 14, 317–348 (2022) https://doi.org/10.1002/dta.3188
Jain M, Joharapurkar A, Patel V, Kshirsagar S, Sutariya B, Patel M, et al. Pharmacological inhibition of prolyl hydroxylase protects against inflammation-induced anemia via efficient erythropoiesis and hepcidin downregulation. Eur. J. Pharmacol., 843, 113–120 (2019) https://doi.org/10.1016/j.ejphar.2018.11.023
Sharma S, Jain S. Bioanalytical perspectives in drug metabolism studies. Drug Metab. Bioanal. Lett., 16, 133–139 (2023) https://doi.org/10.2174/2949681016666230828150206
Solanki J, Parikh PK, Chauhan P, Parikh N. Optimizing quality and sustainability in drug development: a comprehensive desidustat stability study using QbD and green chemistry. J. Liq. Chromatogr. Relat. Technol., 48, 637–652 (2025) https://doi.org/10.1080/10826076.2025.2569880
Reddy GN, Palepu MSK, Sonti R. LC–MS/MS-based investigation of pharmacokinetic interactions between CYP3A4 substrates enzalutamide and repaglinide in rats. Anal. Methods, 17, 9565–9574 (2025) https://doi.org/10.1039/D5AY01451D
Viswanathan CT, Bansal S, Booth B, et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res., 24, 1962–1973 (2007) https://doi.org/10.1007/s11095-007-9291-7
Zhou S, Chan E, Li SC. Critical review of development, validation, and transfer for high throughput bioanalytical LC–MS/MS methods. Curr. Pharm. Anal., 1, 3–14 (2005) https://doi.org/10.2174/1573412052953346
Van Eeckhaut A, Lanckmans K, Sarre S, Smolders I, Michotte Y. Validation of bioanalytical LC–MS/MS assays: evaluation of matrix effects. J. Chromatogr. B, 877, 2198–2207 (2009) https://doi.org/10.1016/j.jchromb.2009.01.003
Patel H, Modi N, Chaudhari J, et al. Nonclinical pharmacokinetic evaluation of desidustat: a novel prolyl hydroxylase inhibitor for the treatment of anemia. Eur. J. Drug Metab. Pharmacokinet., 47, 725–740 (2022) https://doi.org/10.1007/s13318-022-00788-3
Published
How to Cite
Issue
Section
Copyright (c) 2026 Shaik Ayesha Ameen, Nagaraju Pappula

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.







